Adverse effects: nystagmus Duration of treatment (range): 16–18 weeks · people (aged 10–64 years) with drug‐resistant focal epilepsy
Vigabatrin showed no clear difference in adverse effects: nystagmus Duration of treatment (range): 16–18 weeks compared with placebo (low certainty).
1 finding from 1 review
Adverse effects: de novo detrusor overactivity (urodynamic diagnosis) · women with urinary incontinence
Laparoscopic colposuspension showed no clear difference in adverse effects: de novo detrusor overactivity (urodynamic diagnosis) compared with midurethral sling procedures (low certainty).
1 finding from 1 review
Adverse effects: de novo detrusor overactivity (urodynamic diagnosis) · women with urinary incontinence
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: de novo detrusor overactivity (urodynamic diagnosis) · women with urinary incontinence
Laparoscopic colposuspension with sutures showed no clear difference in adverse effects: de novo detrusor overactivity (urodynamic diagnosis) compared with laparoscopic colposuspension with mesh and staples (low certainty).
1 finding from 1 review
Adverse effects: de novo detrusor overactivity (urodynamic diagnosis) · women with urinary incontinence
Laparoscopic colposuspension showed no clear difference in adverse effects: de novo detrusor overactivity (urodynamic diagnosis) compared with open colposuspension (moderate certainty).
1 finding from 1 review
Adverse effects: EPS: dystonia measured by average ESRS change scores · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
FATTY ACID ‐ ETHYL‐EPA showed no clear difference in adverse effects: EPS: dystonia measured by average ESRS change scores compared with PLACEBO (low certainty).
1 finding from 1 review
Adverse effects Defined as any adverse event occurring post‐admission · Patients with non‐trauma related out‐of‐hospital cardiac arrest
1 finding from 1 review
Investigator‐assessed severe adverse effects Application site blister · Moderate and severe acne vulgaris
1 finding from 1 review
Investigator‐assessed severe adverse effects Application site blister · Moderate and severe acne vulgaris
1 finding from 1 review
Adverse effects: measured adverse events ‐ medium term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
HALOPERIDOL may leads to higher adverse effects ‐ movement disorders ‐ At least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
1 finding from 1 review
Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia
Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ movement disorders ‐ at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).
1 finding from 1 review
Weight gain · participants of any age with a primary diagnosis of major depressive disorder
Brexpiprazole probably leads to higher adverse effects: weight gain (followed up until the end of the longest compared with antidepressive agents (moderate certainty).
1 finding from 1 review
Number of major adverse effects defined by the study, before discharge · women with urinary stress incontinence undergoing continence surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: sedation, impaired cognitive function, blurred vision · patients with motion sickness
The review found no eligible studies for this question.
1 finding from 1 review
Proportion of participants with adverse effects ‐ measured over 8 weeks · chronic palmoplantar pustulosis
1 finding from 1 review
Adverse effects: neurological, extrapyramidal UKU (events) Medium‐term · people in the prodromal stage of psychosis
Group A: omega‐3 fatty acids showed no clear difference in adverse effects: neurological, extrapyramidal UKU (events) Medium‐term compared with placebo (low certainty).
1 finding from 1 review
Rash · children diagnosed with Kawasaki disease
It is very uncertain whether TNF‐α blockers intervention changes adverse effects after treatment initiation: cutaneous reactions (rash) compared with placebo or additional treatment (very low certainty).
1 finding from 1 review
Adverse effects: 2. Extrapyramidal ‐ akathisia · female and male 42 (mean) years old patients with schizophrenia or schizoaffective disorder and antipsychotic‐induced tardive dyskinesia
It is very uncertain whether FATTY ACID ‐ ETHYL‐EPA changes adverse effects: EPS: akathisia measured by average ESRS change scores compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: Clinically important general adverse effect (no data) · schizophrenia
1 finding from 1 review